Hong Kong firm invests in Jena-based Oncgnostics GmbH

September 5, 2023

Jena, September 05, 2023. The Hong Kong-based company Grande Bio-tech Co. Ltd. is making a seven-digit Euros investment in the Jena-based diagnostic company Oncgnostics GmbH. Oncgnostics has developed the cancer diagnostic Gyntect for the reliable detection of cervical cancer. Since 2022, this test has also been distributed and utilized in collaboration with a local partner in China. Following the successful launch of Oncgnostics’ test in China, Grande Bio-tech Co. Ltd. has decided to make a financial commitment. The goal now is to expand the distribution of tests developed by Oncgnostics in the ASEAN countries.

Oncgnostics in China since 2022 

After years of close collaboration with a Chinese partner, Oncgnostics’ Gyntect test received approval for the Chinese market in 2022. Since then, the test has been used in China under the name GongAnLi. The Hong Kong-based holding Grande Bio-tech Co. Ltd., has now made a multi-million-dollar investment.

Not every medical product receives approval for China. We’ve succeeded. Now the next step is expanding to whole Asia. Such success is only possible with strong partners.

Dr. Alfred Hansel, Managing Director at Oncgnostics and responsible for international business development

One of these partners is now Grande Bio-tech Co. Ltd., with Mr. Hu Mu as Managing Director, who mentioned, “Oncgnostics is the right partner for us to take big steps in early cancer detection.” 

bm-t and HTGF enable mega-deal

Oncgnostics is a prime example of Thuringia-based companies operating at a global level. That’s why we are further expanding our commitment into Oncgnostics also with respect to pipeline product development.

Mr. Michael Thiele, Senior Investment Manager at bm-t, Beteiligungsmanagement Thüringen GmbH

As an investor from the very beginning, we know the potential of Oncgnostics’ technology. Therefore, we also participated in this financing round.

Dr. Bernd Goergen, partner at High-Tech Gründerfonds

The Gyntect-test 

Gyntect is a swab test that accurately determines within a few hours whether there is a precancerous condition or a tumor on the cervix.

With this test we are able to make quick and reliable assessments of a potential cancer condition. The usual months-long uncertainty until follow-up examinations is eliminated.

Dr. Martina Schmitz, CEO and Scientific Director of Oncgnostics

At the same time, if there is an elevated cancer risk or cancer diagnosis, treatment can be initiated more promptly. The test detects changes in the genetic material of cells and does not require invasive tissue sampling. 

Source: Oncgnostics


About Oncgnostics
Oncgnostics GmbH, a biotech startup spin off from the Jena University Hospital, develops molecular biology tests for cancer diagnostics based on epigenetic changes in the human genome. With Gyntect, the company introduced an innovation in the field of cervical cancer screening. Currently, the startup is developing further tests for head and neck cancers. The team of researchers led by founders Dr. Alfred Hansel (CEO) and Dr. Martina Schmitz (CSO) received the Thuringia Innovation Prize twice (2014, 2017) for their diagnostic approach.  

About High-Tech Gründerfonds
The seed investor High-Tech Gründerfonds (HTGF) finances tech start-ups with growth potential and has supported more than 700 start-ups since 2005. With the launch of its fourth fund, HTGF now has about 1.4 billion euros under management. Its team of experienced investment managers and start-up experts support young companies with expertise, entrepreneurial spirit and passion. HTGF’s focus is on high-tech start-ups in the fields of digital tech, industrial tech, life sciences, chemistry and related business areas. To date, external investors have injected about 5 billion euros of capital into the HTGF portfolio via more than 2,000 follow-on financing rounds. In addition, HTGF has already successfully sold shares in more than 170 companies.
Fund investors in this public-private partnership include the German Federal Ministry for Economic Affairs and Climate Action, KfW Capital and 45 companies from a wide range of industries.

Media contact
High-Tech Gründerfonds Management GmbH
Tobias Jacob, Senior Marketing & Communications Manager
+49 228 82300 121
t.jacob@htgf.de

Stay up to date

Subscribe now and receive the latest press releases on investments and other news from High-Tech Gründerfonds. We inform you about important developments at HTGF and provide you with interesting news from our portfolio. Whether it’s a successful exit, a new exciting investment or HR news – you’ll be the first to know!

Press
16. May 2024

Caeli Wind, the digital platform for wind energy sites, secures €11 million in fresh capital in a Series A funding round.

Notion Capital, Santander Alternative Investments and existing investors provide the digital wind energy pioneer with growth capital for deeper value creation and international expansion. Berlin, London, Madrid (16 May 2024) – Caeli Wind, the platform for analysing and marketing wind energy locations founded by Ben Schlemmermeier and Heiko Bartels in 2022, announced today that it has secured €11 million in growth capital from international investors. The round was led by re
 
Press
7. May 2024

Automated renewable energy planning: Greentech startup everyone energy closes seed financing round

Berlin, 7 May 2024 – Berlin-based greentech startup everyone energy announces the successful closing of its seven-figure seed financing round. The round was led by High-Tech Gründerfonds (HTGF), one of Europe’s leading seed investors, and Cologne-based early-stage VC neoteq ventures. Founded in August 2021 by Céline Göhlich, Fabian Reetz and Florian Gmeiner, everyone energy has quickly established itself as a leading provider of white-label software for customized advisory serv